Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health Corporation is set to report its Q1 earnings on May 1st with analysts expecting revenue of $89 billion and EPS of $1.70. The CVS Health share price has underperformed the S&P 500 Index by almost 20% YTD, presenting a buying opportunity due to its discounted valuation and potential for upside. The recent decline in CVS stock can be attributed to fears of lower-than-expected payment increases for Medicare Advantage Plans, but the decline may now be priced in.

CVS Health: Seizing Opportunity Amid Recent Declines

In the closing of the recent trading day, CVS Health (CVS) stood at $68.64, denoting a -1.58% change from the preceding trading day.

CVS Health (CVS) Declines More Than Market: Some Information for Investors

Advanced Micro Devices

General Motors

In a setting historically dominated by male leadership, women at the helm of major corporations is still considered something of a novelty. You don't see many articles about a company's first male CEO, but there's always a buzz when the first woman gets hired to the same position.

Girl Power Portfolio: 3 High-Potential Stocks With Women CEOs to Buy Now

Abbott Labs

Johnson & Johnson

Patterson Companies

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services.

7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape

SOUTHFIELD, Mich. , April 9, 2024 /PRNewswire/ -- Aetna Better Health of Michigan, a CVS Health® company (NYSE: CVS), has been recommended by the Michigan Department of Health and Human Services to continue serving Medicaid and CHIP beneficiaries under a new Comprehensive Health Care Program (CHCP) contract.

Aetna Better Health of Michigan recommended for CHCP contract

CVS Group's (AIM:CVSG) IT systems have been hit by a cyber attack, which is still affecting some operations at its veterinary practices.  The company said it has informed the Information Commissioner's Office "due to the risk of malicious access to personal information".

Vet chain CVS Group hobbled by cyber attack

Apple

Agree Realty

Automatic Data Processing

Broadcom

Bristol-Myers

Chevron

Dominion Energy

Dollar General

Digital Realty Trust

EOG Resources

Hormel Foods

Kinder Morgan

Lennox International

Mastercard

Medifast

McCormick

Microsoft

NextEra Energy

NXP Semiconductors

Realty Income Corp

Bank OZK

Philip Morris

The stock market shrugged off rising interest rates and global unrest to produce strong gains during 2023.

DGI For The DIY: 2023 Dividend Portfolio Review

Perrigo

CVS Caremark, the pharmacy benefit management subsidiary of CVS Health Corp , will add Perrigo's birth control pill to its preventive services oral contraceptives list and make it available at no cost for many plan sponsors, according to a pharmacy update on March 28.

CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors

The decision by CVS could open the door for more people to prevent unintended pregnancies without a prescription.

Many CVS drug plans will cover over-the-counter birth control pill at no cost

A competition probe into Britain's veterinary market is unlikely to hit CVS Group (AIM:CVSG) PLC and Pets at Home Group PLC (LSE:PETS) as hard as feared, analysts have reassured. The Competition and Markets Authority would likely look to enforce more transparency, rather than taking drastic measures such as forcing disposals and capping product prices, Liberum analysts said in a note.

Vet probe by CMA unlikely to hit CVS, Pets at Home hard - analysts

CVS Health (CVS) closed the most recent trading day at $74.60, moving +1.06% from the previous trading session.

CVS Health (CVS) Outperforms Broader Market: What You Need to Know

Health insurance stocks slid yesterday, after final Medicare Advantage (MA) payment rates fell below expectations.

Why CVS Health Stock Could Stage a Rebound

Walgreens

Zacks Retail-Pharmacies and Drug Stores industry players like CVS and WBA are likely to gain despite reimbursement challenges that are hurting the overall health industry. HLF might face the wrath of economic challenges.

2 Retail Pharmacy Stocks to Watch and One to Avoid Amid Industry Headwinds

Investing in the future of community pharmacy helps ease students' financial barriers and challenges, and promotes a stable and inclusive pharmacy workforce pipeline WOONSOCKET, R.I. , April 3, 2024 /PRNewswire/ -- To support the next generation of pharmacists, CVS Health® (NYSE: CVS) today announced two new offerings for pharmacy students: an enhanced PharmD tuition assistance program for eligible CVS Pharmacy® interns and a new scholarship for students enrolled in pharmacy schools nationwide.

CVS Health® expands pharmacy tuition assistance and scholarship programs

Humana

Humana, CVS, and UnitedHealth all fell after the CMS approved a 3.7% payment rate increase for Medicare Advantage plans for 2025. "Core" payments are actually expected to decline slightly after accounting for higher utilization trends.

Why Shares of UnitedHealth Group, CVS Health, and Humana Fell Today

Centene

Elevance Health Inc

The rate adds more pressure on insurers already grappling with high medical costs and uncertainty after the cyberattack on UnitedHealth Group's tech unit.

Health insurer stocks slide as final Medicare Advantage rates disappoint

Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.

Health Insurance Stocks Drop: Insights Into the Late Monday Fall

Shares of U.S. health insurers dropped between 4% and 9% premarket on Tuesday after reimbursement rates to providers of Medicare Advantage health plans were unchanged from the initial proposal, raising worries about a squeeze on margins next year.

US health insurers slide as final Medicare Advantage rate sparks margin hit fears

Three well-known companies stand out among the market's complexity as excellent opportunities for investors looking for significant gains. Each company operates in the broad domains of pharmaceuticals and healthcare, positioning it strategically to take advantage of new trends and consumer needs.

The Bargain Hunter's Dream: 3 Underpriced Stocks Poised for Massive Gains

CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

WOONSOCKET, R.I. , April 1, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, May 1 st, 2024, at 8:00 a.m.

CVS Health to hold first quarter 2024 earnings conference call

Novo Nordisk

The first major U.S. health insurers have agreed to start paying for the popular anti-obesity drug Wegovy for certain people on Medicare with heart-related conditions.

First Medicare Health Plans to Start Paying for Weight-Loss Drug Wegovy

Hims & Hers Health

Teladoc

The healthcare industry is experiencing extraordinary rapid terrain evolution as advancement meets necessity. Investors are focusing on disruptive businesses during this wave of change.

3 Disruptive Healthcare Stocks That Could Surge 1000% By 2028

Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street Journal.

Wegovy will be covered by some insurers, but not for weight loss: report

CVS Health (CVS) concluded the recent trading session at $79.43, signifying a +0.14% move from its prior day's close.

News for CVS Health Stock (CVS)